OTCMKTS:ENZC Enzolytics (ENZC) Stock Price, News & Analysis → Perma Bull: This is what terrifies me about AI (From InvestorPlace) (Ad) Free ENZC Stock Alerts $0.0035 0.00 (-22.22%) (As of 05/3/2024 08:53 PM ET) Add Compare Share Share Today's Range$0.0031▼$0.004750-Day Range$0.0029▼$0.019552-Week Range$0.00▼$0.13Volume78.15 million shsAverage Volume11.08 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Enzolytics alerts: Email Address Ad InvestorPlacePerma Bull: This is what terrifies me about AIFor 40 years, he's been known as one of the world's most bullish investors. Forbes even referred to him a "perma bull"... But he just shocked the world by issuing a massive bear warning about AI stocks.Go here now for this breaking story. About Enzolytics Stock (OTCMKTS:ENZC)Enzolytics Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company's proprietary cell line produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.Read More ENZC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENZC Stock News HeadlinesMay 1, 2024 | americanbankingnews.comEnzolytics, Inc. (OTCMKTS:ENZC) Sees Significant Increase in Short InterestApril 19, 2024 | finance.yahoo.comEnzolytics, Inc. (ENZC)May 6, 2024 | InvestorPlace (Ad)Perma Bull: This is what terrifies me about AIFor 40 years, he's been known as one of the world's most bullish investors. Forbes even referred to him a "perma bull"... But he just shocked the world by issuing a massive bear warning about AI stocks.April 12, 2024 | finanznachrichten.deEnzolytics, Inc.: Update on Formulation of New Business StrategyMarch 25, 2024 | finance.yahoo.comENZOLYTICS, INC. SHAREHOLDERS HOLD SPECIAL MEETING AND ELECT NEW BOARDFebruary 26, 2024 | benzinga.comEnzolytics Stock (OTC:ENZC) Insider TradesFebruary 22, 2024 | benzinga.comEnzolytics Stock (OTC:ENZC) Earnings Dates and Earning CallsJanuary 16, 2024 | finance.yahoo.comEnzolytics, Inc. Announces Partnership With the Khalpey AI Lab To Forge the Future of Multi-Organ Remodeling and Rejuvenation With a Strategic Focus on LongevityMay 6, 2024 | InvestorPlace (Ad)Perma Bull: This is what terrifies me about AIFor 40 years, he's been known as one of the world's most bullish investors. Forbes even referred to him a "perma bull"... But he just shocked the world by issuing a massive bear warning about AI stocks.November 11, 2023 | morningstar.comEnzolytics Inc ENZCOctober 31, 2023 | benzinga.com"Exploring Penny Stocks: Four Watchlist Options" FTRS, ELTP, ENZC, ZOMSeptember 18, 2023 | finance.yahoo.comEnzolytics Announces the Signing of the Business Combination Agreement with Sagaliam Acquisition Corp (SAGA)September 6, 2023 | finance.yahoo.comPatient Population for the Clinical Trials of ITV-1 has been Established by the European Medicines Agency ("EMA")September 5, 2023 | finance.yahoo.comBiogenysis, Inc. Announces Partnering with Khalpey AI Lab and Contenta, Ltd. to Incorporate AI in Microbiome Analysis to Identify Biomarkers for Use in Accurately Predicting Alzheimer's Disease Onset and Prevention.August 24, 2023 | finance.yahoo.comBiogenysis’ International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application.August 8, 2023 | finance.yahoo.comVirogentics, Inc. Receives Permit for Export to Africa of the ITV-1 Immunotherapy Solidifying the Scheduled Administration of the TreatmentAugust 4, 2023 | finance.yahoo.comVirogentics, Inc. Provides Update on African Project, European Medicine Agency Application and Clinical Trials for Application for Type 2 DiabetesJuly 28, 2023 | benzinga.comOTC Stocks to Watch in August 2023: HNRC, BDPT, ENZC, AABB, SNNCJuly 25, 2023 | finanznachrichten.deEnzolytics, Inc.: Virogentics Announces Approval of Final Protocol from the Dept for HIV and AIDS, Ministry of Health of the DRCJuly 21, 2023 | finance.yahoo.comBiogenysis Inc. Announces a Collaboration with Khalpey AI Lab in using Artificial Intelligence (AI) for Unveiling Potential Biomarkers and Predicting the Onset or Prevention of Alzheimer's Disease.July 6, 2023 | finanznachrichten.deEnzolytics, Inc.: Virogentics, Inc to Introduce a Dietary Supplement Offers Additional Information on ITV-1 And Diabetic Clinical TrialsJuly 6, 2023 | finance.yahoo.comVirogentics, Inc to Introduce a Dietary Supplement Offers Additional Information on ITV-1 And Diabetic Clinical TrialsJune 26, 2023 | finance.yahoo.comEnzolytics Offers Update on Virogentics, Inc ITV-1 African ProjectJune 11, 2023 | sg.finance.yahoo.comENZC - Enzolytics, Inc.June 5, 2023 | finance.yahoo.comEnzolytics Offers Update on Virogentics and Sale Transaction, Clinical Trials Progress on European Medicine Agency (EMA) Permitting and Arican ITV-1 ProjectMay 19, 2023 | finance.yahoo.comVirogentics and Enzolytics Refute Misleading Information Being Circulated on Social Media and Other Internet Outlets Biogenesis to be Featured in June Issue of Life Science ReviewMay 16, 2023 | finanznachrichten.deEnzolytics, Inc.: Virogentics Inc. Receives Report from Bulgarian Academy of Sciences Administration of ITV-1 to Begin First Week in June 2023See More Headlines Receive ENZC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enzolytics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:ENZC CUSIPN/A CIKN/A Webenzolytics.com Phone(972) 292-9414FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Harry H. Zhabilov Jr. (Age 57)BSc, McS Science, CSO & Chairman Steven SharaburaChief Executive OfficerMr. Charles S. CotropiaPresident & DirectorDiana ZhabilovChief Financial OfficerDr. Gaurav Chandra M.D.COO & DirectorDr. Joseph P. Cotropia M.D.Chief Medical Officer & DirectorMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors ENZC Stock Analysis - Frequently Asked Questions How have ENZC shares performed in 2024? Enzolytics' stock was trading at $0.0175 at the start of the year. Since then, ENZC shares have decreased by 80.0% and is now trading at $0.0035. View the best growth stocks for 2024 here. Are investors shorting Enzolytics? Enzolytics saw a increase in short interest in April. As of April 15th, there was short interest totaling 1,387,200 shares, an increase of 16.0% from the March 31st total of 1,196,000 shares. Based on an average trading volume of 28,327,700 shares, the short-interest ratio is currently 0.0 days. View Enzolytics' Short Interest. How do I buy shares of Enzolytics? Shares of ENZC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ENZC) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersNever use this word on your phone (FBI could be watching)Paradigm PressConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsIs this Nvidia's secret weapon?Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldCould Your Accounts Be Frozen?Allegiance GoldElon to Transform U.S. Economy? Porter & CompanyDollar CancelledLear CapitalHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enzolytics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
